Sulbactam Sodium/Ampicillin Sodium — Competitive Intelligence Brief

Sulbactam Sodium/Ampicillin Sodium (Sulbactam Sodium/Ampicillin Sodium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic with beta-lactamase inhibitor. Area: Infectious Disease.

phase 3 Beta-lactam antibiotic with beta-lactamase inhibitor Bacterial penicillin-binding proteins; bacterial beta-lactamases Infectious Disease Small molecule

Target snapshot

Sulbactam Sodium/Ampicillin Sodium (Sulbactam Sodium/Ampicillin Sodium) — Pfizer. Sulbactam inhibits bacterial beta-lactamases while ampicillin inhibits bacterial cell wall synthesis, together providing broad-spectrum bactericidal activity against beta-lactamase-producing organisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sulbactam Sodium/Ampicillin Sodium TARGET	Sulbactam Sodium/Ampicillin Sodium	Pfizer	phase 3	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; bacterial beta-lactamases
Amoxicilline/clavulanic	Amoxicilline/clavulanic	Bayer	phase 3	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; bacterial beta-lactamases
Amoxicillin-Potassium Clavulanate Combination	Amoxicillin-Potassium Clavulanate Combination	Universidad Complutense de Madrid	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Amoxicillin clavulanic	Amoxicillin clavulanic	Hospital Italiano de Buenos Aires	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Piperacillin, Tazobactam Drug Combination	Piperacillin, Tazobactam Drug Combination	Phoenix Children's Hospital	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase enzymes
Piperacillin / Tazobactam Injection	Piperacillin / Tazobactam Injection	Rambam Health Care Campus	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins; bacterial beta-lactamase enzymes
Augmentin®	Augmentin®	Teva Pharmaceuticals USA	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins (PBPs); beta-lactamase enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic with beta-lactamase inhibitor class)

1. Medical University of Vienna · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Phoenix Children's Hospital · 2 drugs in this class
4. Albany Medical College · 2 drugs in this class
5. Pfizer · 2 drugs in this class
6. Imperial College London · 1 drug in this class
7. Hospital Italiano de Buenos Aires · 1 drug in this class
8. Bayer · 1 drug in this class
9. Maggiore Bellaria Hospital, Bologna · 1 drug in this class
10. Kaizen Bioscience Co. · 1 drug in this class